Skip to main content

Advertisement

Log in

Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1

References

  1. Secker-Walker LM, Craig JM, Hawkins JM et al. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5: 196–199.

    CAS  PubMed  Google Scholar 

  2. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.

    Article  CAS  PubMed  Google Scholar 

  3. Westbrook CA, Hooberman AL, Spino C et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80: 2983–2990.

    CAS  PubMed  Google Scholar 

  4. Kantarjian HM, O'Brien S, Smith TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen in, adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547.

    Article  CAS  PubMed  Google Scholar 

  5. Ottmann OG, Druker BJ, Sawyers CL et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971.

    Article  CAS  PubMed  Google Scholar 

  6. Thiesing JT, Ohno-Jones S, Kolibaba KS et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96: 3195–3199.

    CAS  PubMed  Google Scholar 

  7. Aricò M, Valsecchi MG, Camitta B et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998–1006.

    Article  PubMed  Google Scholar 

  8. Dunlop LC, Powles R, Singhal S et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996; 17: 365–369.

    CAS  PubMed  Google Scholar 

  9. Ritz J, Ramsay NK, Kersey JH . Autologous bone marrow transplantation for acute lymphoblastic leukemia. In: Forman S, Blume KG, Thomas ED (eds). Bone marrow Transplantation. Blackwell Scientific Publications: Cambridge, MA, 1994, pp 731–742.

    Google Scholar 

  10. Carella AM, Beltrami G, Corsetti MT . Autografting in chronic myeloid leukemia. Semin Hematol 2003; 40: 72–78.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shin, HJ., Chung, J. & Cho, G. Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 36, 917–918 (2005). https://doi.org/10.1038/sj.bmt.1705144

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705144

  • Springer Nature Limited

This article is cited by

Navigation